Thymoquinone Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱

Features: Anti-oxidant, anti-tumor

Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank	Pathway / Target Axis	Direction	Label	Primary Effect	Notes / Cancer Relevance	Ref
1	Reactive oxygen species (ROS)	↑ ROS	Driver	Upstream cytotoxic trigger	Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts	(ref)
2	Glutathione (GSH) redox buffering	↓ GSH	Driver	Redox-collapse amplification	Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells	(ref)
3	Mitochondrial integrity (ΔΨm)	↓ ΔΨm	Driver	Mitochondrial dysfunction (MOMP axis)	Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death)	(ref)
4	Intrinsic apoptosis (caspase-9 → caspase-3; PARP)	↑ caspases / ↑ apoptosis	Driver	Execution-phase cell death	Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway	(ref)
5	NF-κB signaling	↓ NF-κB activity	Secondary	Reduced pro-survival / inflammatory transcription	Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support)	(ref)
6	STAT3 signaling	↓ p-STAT3 / ↓ STAT3 activation	Secondary	Reduced survival/proliferation signaling	Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts	(ref)
7	NRF2 antioxidant-response axis (NRF2/HO-1 program)	↑ NRF2 pathway (often as stress-response)	Adaptive	Cellular antioxidant counter-response	In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress	(ref)
8	HIF-1α hypoxia signaling	↓ HIF-1α protein / ↓ HIF-1α program	Adaptive	Loss of hypoxia survival signaling	Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia	(ref)
9	Glycolysis / Warburg output (hypoxia-linked)	↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism)	Phenotypic	Metabolic suppression	In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation	(ref) \| (ref)

Scientific Papers found: Click to Expand⟱

4774-

5-FU,

TQ,

CoQ10,

Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation

in-vitro,

CRC,

"highlight2" >AntiCan↑, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >eff↑, "highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >P21↑, "highlight2" >p27/CDKN1B↑, "highlight2" >BAX↑, "highlight2" >Cyt‑c↑, "highlight2" >Casp3↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >Hif1a↓, "highlight2" >PTEN↑, "highlight2" >AMPKα↑, "highlight2" >PDH↑, "highlight2" >LDHA↓, "highlight2" >antiOx↓, "highlight2" >ROS↑, "highlight2" >AntiCan↑,

2207-

AgNPs,

TQ,

Protective effects of Nigella sativa L. seeds aqueous extract-based silver nanoparticles on sepsis-induced damages in rats

in-vivo,

Nor,

Rats

"highlight2" >*eff↑, "highlight2" >*RenoP↑, "highlight2" >*hepatoP↑, "highlight2" >*MDA↓, "highlight2" >*SOD↑, "highlight2" >*GSH↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓,

1920-

JG,

TQ,

PLB,

Natural quinones induce ROS-mediated apoptosis and inhibit cell migration in PANC-1 human pancreatic cancer cell line

in-vitro,

PC,

PANC1

"highlight2" >ROS↑, "highlight2" >TumCMig↓, "highlight2" >MMP9↓,

4670-

RES,

CUR,

EGCG,

TQ,

Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol

Review,

Nor,

"highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*AntiAge↑, "highlight2" >*SIRT1↑, "highlight2" >*SIRT3↑, "highlight2" >*FOXO↑, "highlight2" >*ROS↓,

3419-

TQ,

Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients

in-vitro,

BC,

PBMCs isolated from HR+ BC patients were treated with increasing concentrations of TQ (20, 50, and 100 µM) for 24, 48, and 72 h.

 peripheral blood mononuclear cells (PBMCs)

"highlight2" >*NLRP3↓, "highlight2" >*IL1β↓, "highlight2" >*Casp1?,

3411-

TQ,

Anticancer and Anti-Metastatic Role of Thymoquinone: Regulation of Oncogenic Signaling Cascades by Thymoquinone

Review,

Var,

"highlight2" >p‑STAT3↓, "highlight2" >cycD1/CCND1↓, "highlight2" >JAK2↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >cMyc↓, "highlight2" >MMP7↓, "highlight2" >MET↓, "highlight2" >p‑Akt↓, "highlight2" >p‑mTOR↓, "highlight2" >CXCR4↓, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >ROS↑, "highlight2" >Cyt‑c↑, "highlight2" >Twist↓, "highlight2" >Zeb1↓, "highlight2" >E-cadherin↑, "highlight2" >p‑p38↑, "highlight2" >p‑MAPK↑, "highlight2" >ERK↑, "highlight2" >eff↑, "highlight2" >ERK↓, "highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓,

3412-

TQ,

Thymoquinone induces oxidative stress-mediated apoptosis through downregulation of Jak2/STAT3 signaling pathway in human melanoma cells

in-vitro,

Melanoma,

SK-MEL-28

in-vivo,

NA,

SK-MEL-28 tumor xenografts

"highlight2" >Apoptosis↑, "highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >cycD1/CCND1↓, "highlight2" >survivin↓, "highlight2" >ROS↑, "highlight2" >eff↓,

3413-

TQ,

Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase

in-vitro,

CRC,

HCT116

"highlight2" >tumCV↓, "highlight2" >Apoptosis↓, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >Casp9↑, "highlight2" >Casp7↑, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >STAT3↓, "highlight2" >survivin↓, "highlight2" >cMyc↓, "highlight2" >cycD1/CCND1↓, "highlight2" >p27/CDKN1B↑, "highlight2" >P21↑, "highlight2" >EGFR↓, "highlight2" >ROS↑,

3414-

TQ,

Thymoquinone induces apoptosis through inhibition of JAK2/STAT3 signaling via production of ROS in human renal cancer Caki cells

in-vitro,

RCC,

Caki-1

"highlight2" >tumCV↓, "highlight2" >Apoptosis↑, "highlight2" >P53↑, "highlight2" >BAX↑, "highlight2" >Cyt‑c↑, "highlight2" >cl‑Casp9↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >Bcl-2↓, "highlight2" >Bcl-xL↓, "highlight2" >p‑STAT3↓, "highlight2" >p‑JAK2↓, "highlight2" >STAT3↓, "highlight2" >survivin↓, "highlight2" >cycD1/CCND1↓, "highlight2" >ROS↑, "highlight2" >eff↓,

3415-

TQ,

The anti-neoplastic impact of thymoquinone from Nigella sativa on small cell lung cancer: In vitro and in vivo investigations

in-vitro,

Lung,

H446

1-100uM

"highlight2" >tumCV↓, "highlight2" >TumCCA↑, "highlight2" >ROS↓, "highlight2" >CycB/CCNB1↑, "highlight2" >CycD3↑, "highlight2" >cycA1/CCNA1↓, "highlight2" >cycE/CCNE↓, "highlight2" >cDC2↓, "highlight2" >antiOx↑, "highlight2" >PARP↓, "highlight2" >NRF2↓, "highlight2" >ARE/EpRE↑, "highlight2" >eff↑,

3416-

TQ,

Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway

in-vitro,

Bladder,

T24/HTB-9

 TQ (20–100 μM) for 24 h

in-vitro,

Bladder,

253J

in-vitro,

Nor,

SV-HUC-1

"highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >ER Stress↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp8↑, "highlight2" >cl‑Casp7↑, "highlight2" >cl‑PARP↑, "highlight2" >Cyt‑c↑, "highlight2" >PERK↑, "highlight2" >IRE1↑, "highlight2" >ATF6↑, "highlight2" >p‑eIF2α↑, "highlight2" >ATF4↑, "highlight2" >GRP78/BiP↑, "highlight2" >CHOP/DDIT3↑,

3417-

TQ,

Antiproliferative Effects of Thymoquinone in MCF-7 Breast and HepG2 Liver Cancer Cells: Possible Role of Ceramide and ER Stress

in-vitro,

BC,

MCF7

in-vitro,

Liver,

HepG2

"highlight2" >TumCP↓, "highlight2" >NF-kB↓, "highlight2" >cl‑Casp3↑, "highlight2" >GRP78/BiP↑, "highlight2" >ER Stress↑, "highlight2" >Apoptosis↑,

3418-

TQ,

Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome

in-vitro,

Melanoma,

A375

in-vivo,

NA,

B16F10) melanoma cell line

"highlight2" >TumMeta↓, "highlight2" >TumCMig↓, "highlight2" >NLRP3↓, "highlight2" >Casp1↓, "highlight2" >IL1β↓, "highlight2" >IL18↓, "highlight2" >ROS↓, "highlight2" >NF-kB↓,

3408-

TQ,

Thymoquinone: A small molecule from nature with high therapeutic potential

Review,

AD,

Review,

Park,

"highlight2" >*neuroP↑, "highlight2" >*hepatoP↑, "highlight2" >*cardioP↑, "highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >angioG↓, "highlight2" >cycA1/CCNA1↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >CDK2↓,

3420-

TQ,

Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway

in-vitro,

Nor,

HUVECs

in-vitro,

NA,

rat

"highlight2" >*NF-kB↓, "highlight2" >*NLRP3↓, "highlight2" >*angioG↑, "highlight2" >*MMP9↑, "highlight2" >*VEGF↑, "highlight2" >*OS↑, "highlight2" >*Pyro?, "highlight2" >*ROS↓, "highlight2" >*Apoptosis↓, "highlight2" >*SIRT1↑, "highlight2" >*SOD1↑, "highlight2" >*HO-1↑, "highlight2" >*eNOS↑, "highlight2" >*ASC?, "highlight2" >*Casp1↓, "highlight2" >*IL1β↓, "highlight2" >*IL18↓,

3421-

TQ,

Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer

Analysis,

Nor,

in-vivo,

Nor,

in-vitro,

BC,

MCF7

in-vitro,

Nor,

HaCaT

"highlight2" >HDAC↓, "highlight2" >P21↑, "highlight2" >Maspin↑, "highlight2" >BAX↑, "highlight2" >B2M↓, "highlight2" >TumCCA↑, "highlight2" >selectivity↑, "highlight2" >*toxicity↓, "highlight2" >TumCMig↓, "highlight2" >TumCP↓,

3422-

TQ,

Thymoquinone, as a Novel Therapeutic Candidate of Cancers

Review,

Var,

"highlight2" >selectivity↑, "highlight2" >P53↑, "highlight2" >PTEN↑, "highlight2" >NF-kB↓, "highlight2" >PPARγ↓, "highlight2" >cMyc↓, "highlight2" >Casp↑, "highlight2" >*BioAv↓, "highlight2" >BioAv↝, "highlight2" >eff↑, "highlight2" >survivin↓, "highlight2" >Bcl-xL↓, "highlight2" >Bcl-2↓, "highlight2" >Akt↓, "highlight2" >BAX↑, "highlight2" >cl‑PARP↑, "highlight2" >CXCR4↓, "highlight2" >MMP9↓, "highlight2" >VEGFR2/KDR/Flk1↓, "highlight2" >Ki-67↓, "highlight2" >COX2/PTGS2↓, "highlight2" >JAK2↓, "highlight2" >cSrc↓, "highlight2" >Apoptosis↑, "highlight2" >p‑STAT3↓, "highlight2" >cycD1/CCND1↓, "highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >Casp9↑, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >Twist↓, "highlight2" >E-cadherin↑, "highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >EMT↓, "highlight2" >ROS↑, "highlight2" >DNMT1↓, "highlight2" >eff↑, "highlight2" >EZH2↓, "highlight2" >hepatoP↑, "highlight2" >Zeb1↓, "highlight2" >RadioS↑, "highlight2" >HDAC↓, "highlight2" >HDAC1↓, "highlight2" >HDAC2↓, "highlight2" >HDAC3↓, "highlight2" >*NAD↑, "highlight2" >*SIRT1↑, "highlight2" >SIRT1↓, "highlight2" >*Inflam↓, "highlight2" >*CRP↓, "highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*IL1β↓, "highlight2" >*eff↑, "highlight2" >*MDA↓, "highlight2" >*NO↓, "highlight2" >*GSH↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >*GPx↑, "highlight2" >PI3K↓, "highlight2" >mTOR↓,

3423-

TQ,

Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics

Review,

Var,

"highlight2" >AntiCan↑, "highlight2" >Inflam↓, "highlight2" >hepatoP↑, "highlight2" >RenoP↑, "highlight2" >BAX↑, "highlight2" >Bak↑, "highlight2" >Bcl-2↓, "highlight2" >Bcl-xL↓, "highlight2" >ROS↑, "highlight2" >P53↑, "highlight2" >PTEN↑, "highlight2" >P21↑, "highlight2" >p27/CDKN1B↑, "highlight2" >BRCA1↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >MAPK↓, "highlight2" >ERK↓, "highlight2" >p‑ERK↓, "highlight2" >MMPs↓, "highlight2" >FAK↓, "highlight2" >Twist↓, "highlight2" >Zeb1↓, "highlight2" >EMT↓, "highlight2" >TumMeta↓, "highlight2" >angioG↓, "highlight2" >VEGF↓, "highlight2" >HDAC↓, "highlight2" >Maspin↑, "highlight2" >SIRT1↑, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >HDAC1↓, "highlight2" >HDAC4↓,

3424-

TQ,

Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

Review,

Var,

"highlight2" >DNMT1↓, "highlight2" >HDAC1↓, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >Apoptosis↑, "highlight2" >angioG↓, "highlight2" >TumMeta↓, "highlight2" >selectivity↑, "highlight2" >BioAv↓, "highlight2" >BioAv↓, "highlight2" >HDAC1↓, "highlight2" >HDAC4↓, "highlight2" >UHRF1↓, "highlight2" >selectivity↑, "highlight2" >G9a↓,

3425-

TQ,

Advances in research on the relationship between thymoquinone and pancreatic cancer

"highlight2" >Apoptosis↑, "highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >TumMeta↓, "highlight2" >ChemoSen↑, "highlight2" >angioG↓, "highlight2" >Inflam↓, "highlight2" >NF-kB↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >TGF-β↓, "highlight2" >Jun↓, "highlight2" >p38↑, "highlight2" >MAPK↑, "highlight2" >MMP9↓, "highlight2" >PKM2↓, "highlight2" >ROS↑, "highlight2" >JNK↑, "highlight2" >MUC4↓, "highlight2" >TGF-β↑, "highlight2" >Dose↝, "highlight2" >FAK↓, "highlight2" >NOTCH↓, "highlight2" >PTEN↑, "highlight2" >mTOR↓, "highlight2" >Warburg↓, "highlight2" >XIAP↓, "highlight2" >COX2/PTGS2↓, "highlight2" >Casp9↑, "highlight2" >Ki-67↓, "highlight2" >CD34↓, "highlight2" >VEGF↓, "highlight2" >MCP1/CCL2↓, "highlight2" >survivin↓, "highlight2" >Cyt‑c↑, "highlight2" >Casp3↑, "highlight2" >H4↑, "highlight2" >HDAC↓,

3426-

TQ,

Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms

in-vitro,

BC,

MDA-MB-468

in-vitro,

AML,

24 h with 20 µM of TQ

"highlight2" >UHRF1↓, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >DNMTs↓, "highlight2" >HDAC1↓, "highlight2" >HDAC4↓, "highlight2" >HDAC↓, "highlight2" >DLC1↑, "highlight2" >PPARγ↑, "highlight2" >FOXO↑, "highlight2" >TET2↑, "highlight2" >CYP1B1↑, "highlight2" >G9a↓,

3402-

TQ,

Enhanced Apoptosis in Pancreatic Cancer Cells through Thymoquinone-rich Nigella sativa L. Methanol Extract: Targeting NRF2/HO-1 and TNF-α Pathways

in-vitro,

PC,

PANC1

in-vitro,

PC,

MIA PaCa-2

"highlight2" >tumCV↓, "highlight2" >NRF2↑, "highlight2" >HO-1↑, "highlight2" >TNF-α↓,

2138-

TQ,

Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice

in-vivo,

Nor,

TQ (5 mg/kg

Male C57 mice were used to establish an ischemic stroke model by using endothelin-1

"highlight2" >*Hif1a↑, "highlight2" >*VEGF↑, "highlight2" >*TrkB↑, "highlight2" >*PI3K↑, "highlight2" >*angioG↑, "highlight2" >*neuroG↑, "highlight2" >*motorD↑,

2139-

TQ,

Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway

in-vivo,

Nor,

acute ischemic stroke using a mouse middle cerebral artery ischemia-reperfusion (I/R) model.

"highlight2" >*TLR4↓, "highlight2" >*NF-kB↓, "highlight2" >*Inflam↓, "highlight2" >*Hif1a↑, "highlight2" >*motorD↑,

2353-

TQ,

The effects of thymoquinone on pancreatic cancer: Evidence from preclinical studies

Review,

PC,

"highlight2" >BioAv↝, "highlight2" >BioAv↑, "highlight2" >MUC4↓, "highlight2" >PKM2↓, "highlight2" >eff↑, "highlight2" >TumVol↓, "highlight2" >HDAC↓, "highlight2" >NF-kB↓, "highlight2" >Bcl-2↓, "highlight2" >Bcl-xL↓, "highlight2" >survivin↓, "highlight2" >XIAP↓, "highlight2" >COX2/PTGS2↓, "highlight2" >PGE1↓,

3397-

TQ,

Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer

Review,

CRC,

6-112uM (table 1)

"highlight2" >ChemoSen↑, "highlight2" >*Half-Life↝, "highlight2" >*BioAv↝, "highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*hepatoP↑, "highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >angioG↑, "highlight2" >selectivity↑, "highlight2" >JNK↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 147

Pathway results for Effect on Cancer / Diseased Cells:

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,
Total Targets: 198

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 7, Catalase↑, 6, GPx↑, 3, GPx4↑, 1, GSH↑, 8, GSR↑, 2, GSTA1↑, 1, GSTs↑, 2, HO-1↑, 5, lipid-P↓, 3, MDA↓, 6, MPO↓, 1, NOX4↓, 1, NQO1↑, 1, NRF2↑, 8, ROS↓, 13, SIRT3↑, 1, SOD↑, 7, SOD1↑, 1, TAC↑, 2, Thiols↑, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1, BUN↓, 1, CREB↑, 1, p‑CREB↑, 1, LDH↓, 1, NAD↑, 1, SIRT1↑, 3,

Cell Death(tgid=5) ⓘ

Apoptosis↓, 3, Casp1?, 1, Casp1↓, 1, Casp3↓, 3, iNOS↓, 2, iNOS↑, 1, JNK↑, 1, MAPK↓, 1, p38↓, 1, Pyro?, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↑, 1, FOXO↑, 1, p‑mTOR↓, 1, neuroG↑, 1, PI3K↑, 1,

Migration(tgid=13) ⓘ

MMP13↓, 2, MMP9↑, 1, TGF-β↓, 2,

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 2, eNOS↑, 1, Hif1a↑, 2, NO↓, 1, VEGF↑, 2,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

ASC?, 1, COX2/PTGS2↓, 5, CRP↓, 2, CXCc↓, 1, IFN-γ↓, 2, IL10↑, 1, IL12↓, 2, IL18↓, 1, IL1β↓, 13, IL6↓, 5, Inflam↓, 11, IP-10/CXCL-10↓, 1, MCP1/CCL2↓, 2, MyD88↓, 2, NF-kB↓, 8, PGE2↓, 4, TLR2↓, 2, TLR4↓, 3, TNF-α↓, 10, TRIF↓, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↝, 1, BDNF↑, 1, BDNF∅, 1, GABA↑, 1, p‑tau↓, 1, TrkB↑, 1,

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 3, BACE/β-secretase↓, 1, NLRP3↓, 2,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2, BioAv↑, 2, BioAv↝, 1, eff↑, 3, Half-Life↝, 1,

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1, ALP↓, 1, AST↓, 1, CRP↓, 2, IL6↓, 5, LDH↓, 1,

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1, cardioP↑, 4, cognitive↑, 3, hepatoP↑, 4, memory↑, 2, motorD↑, 2, neuroP↑, 5, OS↑, 1, radioP↑, 1, RenoP↑, 5, toxicity↓, 1,

Infection & Microbiome(tgid=24) ⓘ

IRF3↓, 2,
Total Targets: 106

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Thymoquinone Cancer Research Results

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Kinase & Signal Transduction(tgid=6) ⓘ

Transcription & Epigenetics(tgid=7) ⓘ

Protein Folding & ER Stress(tgid=8) ⓘ

Autophagy & Lysosomes(tgid=9) ⓘ

DNA Damage & Repair(tgid=10) ⓘ

Cell Cycle & Senescence(tgid=11) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Protein Aggregation(tgid=19) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

Core Metabolism/Glycolysis(tgid=4) ⓘ

Cell Death(tgid=5) ⓘ

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Migration(tgid=13) ⓘ

Angiogenesis & Vasculature(tgid=14) ⓘ

Barriers & Transport(tgid=15) ⓘ

Immune & Inflammatory Signaling(tgid=16) ⓘ

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

Drug Metabolism & Resistance(tgid=21) ⓘ

Clinical Biomarkers(tgid=22) ⓘ

Functional Outcomes(tgid=23) ⓘ

Infection & Microbiome(tgid=24) ⓘ

Home Page